Macrophages are key immune cells in the activation and regulation of immune responses. These cells are present in all tissues under homeostatic conditions and in many disease settings. Macrophages can exhibit a wide range of phenotypes depending on local and systemic cues that drive the differentiation and activation process. Macrophage heterogeneity is also defined by their ontogeny. Tissue macrophages can either derive from circulating blood monocytes or are seeded as tissue-resident macrophages during embryonic development. In humans, the study of in vivo-generated macrophages is often difficult with laborious and cell-changing isolation procedures. Therefore, translatable, reproducible, and robust in vitro models for human macrophages in health and disease are necessary. Most of the methods for studying monocytederived macrophages are based on the use of limited factors to differentiate the monocytes into macrophages. Current knowledge shows that the in vivo situation is more complex, and a wide range of molecules in the tissue microenvironment promote and impact on monocyte to macrophage differentiation as well as activation. In this review, macrophage heterogeneity is discussed and the human in vitro models that can be applied for research, especially for monocytederived macrophages. We also focus on new molecules (IL-34, platelet factor 4, etc.) used to generate macrophages expressing different phenotypes. K E Y W O R D S macrophages, monocytes, Immunotherapy, innate cell mediated immunity, in vitro model 1 INTRODUCTION Macrophages are immune cells with heterogeneous phenotypes and complex functions in tissue homeostasis and innate and acquired immunity. These cells belong to the mononuclear phagocyte system (MPS). 1-3 In the original MPS model, macrophages present in the tissues were all thought to be derived from monocytes. 4 In the 2000s this concept started to change when lineage-tracing studies showed that populations of macrophages with different origins were found in Abbreviations: BHA, Butylated hidroxyanisole; CaOx, Calcium oxalate; CD200, cluster of differentiation molecule 200; CRISPR/Cas9, clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9; CX 3 CL 1 , Fractalkine; CX 3 CR 1 , fractalkine receptor; HIF-1 /HIF-1 , Hypoxia-inducible factor 1 / ; HSC, hematopoietic stem cell; iPSC, induced pluripotent stem cells; iPSDM, iPSC-derived macrophages; IRF4/5, IFN regulatory factor 4/5; LIPA, Lysosomal acid lipase; LL-37, Cathelicidin antimicrobial peptides LL-37; MDM, monocyte-derived macrophage; MPS, mononuclear phagocyte system; PF4, Platelet factor 4; TREM2, Triggering receptor expressed on myeloid cells 2. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.